Bone Loss in Inflammatory Rheumatic Musculoskeletal Disease Patients Treated With Low‐Dose Glucocorticoids and Prevention by Anti‐Osteoporosis Medications
Arthritis & Rheumatology · 2023
DOI: 10.1002/art.42529 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2023. Verfasst von Giovanni Adami und 7 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Unit, University of Verona, Verona, Italy. Hauptthemen laut MEDLINE: Fractures, Bone, Glucocorticoids, Osteoporosis, Prednisone. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
The negative effects of glucocorticoids on bone depend on dose and treatment duration. However, it is unclear whether a safe dose exists, especially for patients with inflammatory rheumatic musculoskeletal diseases (iRMDs). We undertook this study to determine the effects of glucocorticoid doses on bone health in iRMD patients.
Methods
We conducted a longitudinal cohort study on women with iRMD. Bone mineral density (BMD) and fractures were assessed prospectively and compared to a matched cohort without iRMD. Kaplan‐Meier curves with log rank test were made for iRMD patients (stratified for glucocorticoid use and dose) and the matched cohort. Multivariable Cox regression survival models were also employed to analyze the effect of glucocorticoids on fracture.
Results
A total of 884 women with iRMD and 1,766 controls (matched for age, T score, and 10‐year fracture risk) were included in the study and followed up for up to 6 years. BMD decreased significantly in all patients receiving glucocorticoids who were not receiving anti‐osteoporosis treatment (–4.26% for ≥5 mg/day of prednisone equivalent, P = 0.0011; –4.23% for 2.5–5 mg/day, P = 0.0422; –2.66% for 0–2.5 mg/day, P = 0.0006). Anti‐osteoporosis treatment (largely bisphosphonates) prevented bone loss only in patients receiving
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Rheumatology Unit, University of Verona, Verona, Italy.
ORCID-Profile: Giovanni Adami, Davide Bertelle
Zitieren
APA
Adami, G., Fassio, A., Rossini, M., Benini, C., Pistillo, F., Viapiana, O., Bertelle, D., & Gatti, D. (2023). Bone Loss in Inflammatory Rheumatic Musculoskeletal Disease Patients Treated With Low‐Dose Glucocorticoids and Prevention by Anti‐Osteoporosis Medications. Arthritis & Rheumatology. https://doi.org/10.1002/art.42529
Vancouver
Adami G, Fassio A, Rossini M, Benini C, Pistillo F, Viapiana O, et al. Bone Loss in Inflammatory Rheumatic Musculoskeletal Disease Patients Treated With Low‐Dose Glucocorticoids and Prevention by Anti‐Osteoporosis Medications. Arthritis & Rheumatology. 2023. doi:10.1002/art.42529
BibTeX
@article{Adami2023,
author = {Adami, Giovanni and Fassio, Angelo and Rossini, Maurizio and Benini, Camilla and Pistillo, Francesca and Viapiana, Ombretta and Bertelle, Davide and Gatti, Davide},
title = {Bone Loss in Inflammatory Rheumatic Musculoskeletal Disease Patients Treated With Low‐Dose Glucocorticoids and Prevention by Anti‐Osteoporosis Medications},
journal = {Arthritis & Rheumatology},
year = {2023},
doi = {10.1002/art.42529}
}
EUVIMED